Replication study to confirm the role of CYP2D6 polymorphism rs1080985 on donepezil efficacy in alzheimer's disease patients

Diego Albani; Filippo Martinelli Boneschi; Gloria Biella; Giacomo Giacalone; Sara Lupoli; Francesca Clerici; Luisa Benussi; Roberta Ghidoni; Daniela Galimberti; Rosanna Squitti; Stefania Mariani; Annamaria Confaloni; Giuseppe Bruno; Claudio Mariani; Elio Scarpini; Giuliano Binetti; Giuseppe Magnani; Massimo Franceschi; Gianluigi Forloni

doi:10.3233/JAD-2012-112123

Replication study to confirm the role of CYP2D6 polymorphism rs1080985 on donepezil efficacy in alzheimer's disease patients

Diego Albani, Filippo Martinelli Boneschi, Gloria Biella, Giacomo Giacalone, Sara Lupoli, Francesca Clerici, Luisa Benussi, Roberta Ghidoni, Daniela Galimberti, Rosanna Squitti, Stefania Mariani, Annamaria Confaloni, Giuseppe Bruno, Claudio Mariani, Elio Scarpini, Giuliano Binetti, Giuseppe Magnani, Massimo Franceschi, Gianluigi Forloni

Research output: Contribution to journal › Article › peer-review

Abstract

Alzheimer's disease (AD) is a neurodegenerative disorder often treated with donepezil, an acetylcholinesterase inhibitor. Response to donepezil is variable, probably based on patients' genetic background in donepezil metabolizing enzymes, including cytochrome 2D6 (CYP2D6). We evaluated the association between clinical response to donepezil and a common variant (rs1080985) of CYP2D6, previously reported to be associated with poor response to the drug. In a sample of 415 AD cases, we found evidence of association between rs1080985 and response to donepezil after 6 months of therapy (OR [95% CI]: 1.74 [1.01-3.00], p = 0.04). Rs1080985 might be useful as predictor of poor response to short-term donepezil treatment.

Original language	English
Pages (from-to)	745-749
Number of pages	5
Journal	Journal of Alzheimer's Disease
Volume	30
Issue number	4
DOIs	https://doi.org/10.3233/JAD-2012-112123
Publication status	Published - 2012

Keywords

Alzheimer's disease
apolipoprotein E
CYP2D6
donepezil
pharmacogenetics
rs1080985

ASJC Scopus subject areas

Psychiatry and Mental health
Geriatrics and Gerontology
Clinical Psychology

Access to Document

10.3233/JAD-2012-112123

Fingerprint Dive into the research topics of 'Replication study to confirm the role of CYP2D6 polymorphism rs1080985 on donepezil efficacy in alzheimer's disease patients'. Together they form a unique fingerprint.

Cite this

Albani, D., Boneschi, F. M., Biella, G., Giacalone, G., Lupoli, S., Clerici, F., Benussi, L., Ghidoni, R., Galimberti, D., Squitti, R., Mariani, S., Confaloni, A., Bruno, G., Mariani, C., Scarpini, E., Binetti, G., Magnani, G., Franceschi, M., & Forloni, G. (2012). Replication study to confirm the role of CYP2D6 polymorphism rs1080985 on donepezil efficacy in alzheimer's disease patients. Journal of Alzheimer's Disease, 30(4), 745-749. https://doi.org/10.3233/JAD-2012-112123

Replication study to confirm the role of CYP2D6 polymorphism rs1080985 on donepezil efficacy in alzheimer's disease patients. / Albani, Diego; Boneschi, Filippo Martinelli; Biella, Gloria; Giacalone, Giacomo; Lupoli, Sara; Clerici, Francesca; Benussi, Luisa ; Ghidoni, Roberta ; Galimberti, Daniela; Squitti, Rosanna; Mariani, Stefania; Confaloni, Annamaria; Bruno, Giuseppe; Mariani, Claudio; Scarpini, Elio ; Binetti, Giuliano ; Magnani, Giuseppe; Franceschi, Massimo; Forloni, Gianluigi.

In: Journal of Alzheimer's Disease, Vol. 30, No. 4, 2012, p. 745-749.

Research output: Contribution to journal › Article › peer-review

Albani, D, Boneschi, FM, Biella, G, Giacalone, G, Lupoli, S, Clerici, F, Benussi, L , Ghidoni, R , Galimberti, D, Squitti, R, Mariani, S, Confaloni, A, Bruno, G, Mariani, C, Scarpini, E , Binetti, G , Magnani, G, Franceschi, M & Forloni, G 2012, 'Replication study to confirm the role of CYP2D6 polymorphism rs1080985 on donepezil efficacy in alzheimer's disease patients', Journal of Alzheimer's Disease, vol. 30, no. 4, pp. 745-749. https://doi.org/10.3233/JAD-2012-112123

Albani, Diego ; Boneschi, Filippo Martinelli ; Biella, Gloria ; Giacalone, Giacomo ; Lupoli, Sara ; Clerici, Francesca ; Benussi, Luisa ; Ghidoni, Roberta ; Galimberti, Daniela ; Squitti, Rosanna ; Mariani, Stefania ; Confaloni, Annamaria ; Bruno, Giuseppe ; Mariani, Claudio ; Scarpini, Elio ; Binetti, Giuliano ; Magnani, Giuseppe ; Franceschi, Massimo ; Forloni, Gianluigi. / Replication study to confirm the role of CYP2D6 polymorphism rs1080985 on donepezil efficacy in alzheimer's disease patients. In: Journal of Alzheimer's Disease. 2012 ; Vol. 30, No. 4. pp. 745-749.

@article{04cdcbb94a094fcb815f54249a0ec0de,

title = "Replication study to confirm the role of CYP2D6 polymorphism rs1080985 on donepezil efficacy in alzheimer's disease patients",

abstract = "Alzheimer's disease (AD) is a neurodegenerative disorder often treated with donepezil, an acetylcholinesterase inhibitor. Response to donepezil is variable, probably based on patients' genetic background in donepezil metabolizing enzymes, including cytochrome 2D6 (CYP2D6). We evaluated the association between clinical response to donepezil and a common variant (rs1080985) of CYP2D6, previously reported to be associated with poor response to the drug. In a sample of 415 AD cases, we found evidence of association between rs1080985 and response to donepezil after 6 months of therapy (OR [95% CI]: 1.74 [1.01-3.00], p = 0.04). Rs1080985 might be useful as predictor of poor response to short-term donepezil treatment.",

keywords = "Alzheimer's disease, apolipoprotein E, CYP2D6, donepezil, pharmacogenetics, rs1080985",

author = "Diego Albani and Boneschi, {Filippo Martinelli} and Gloria Biella and Giacomo Giacalone and Sara Lupoli and Francesca Clerici and Luisa Benussi and Roberta Ghidoni and Daniela Galimberti and Rosanna Squitti and Stefania Mariani and Annamaria Confaloni and Giuseppe Bruno and Claudio Mariani and Elio Scarpini and Giuliano Binetti and Giuseppe Magnani and Massimo Franceschi and Gianluigi Forloni",

year = "2012",

doi = "10.3233/JAD-2012-112123",

language = "English",

volume = "30",

pages = "745--749",

journal = "Journal of Alzheimer's Disease",

issn = "1387-2877",

publisher = "IOS Press",

number = "4",

}

TY - JOUR

T1 - Replication study to confirm the role of CYP2D6 polymorphism rs1080985 on donepezil efficacy in alzheimer's disease patients

AU - Albani, Diego

AU - Boneschi, Filippo Martinelli

AU - Biella, Gloria

AU - Giacalone, Giacomo

AU - Lupoli, Sara

AU - Clerici, Francesca

AU - Benussi, Luisa

AU - Ghidoni, Roberta

AU - Galimberti, Daniela

AU - Squitti, Rosanna

AU - Mariani, Stefania

AU - Confaloni, Annamaria

AU - Bruno, Giuseppe

AU - Mariani, Claudio

AU - Scarpini, Elio

AU - Binetti, Giuliano

AU - Magnani, Giuseppe

AU - Franceschi, Massimo

AU - Forloni, Gianluigi

PY - 2012

Y1 - 2012

N2 - Alzheimer's disease (AD) is a neurodegenerative disorder often treated with donepezil, an acetylcholinesterase inhibitor. Response to donepezil is variable, probably based on patients' genetic background in donepezil metabolizing enzymes, including cytochrome 2D6 (CYP2D6). We evaluated the association between clinical response to donepezil and a common variant (rs1080985) of CYP2D6, previously reported to be associated with poor response to the drug. In a sample of 415 AD cases, we found evidence of association between rs1080985 and response to donepezil after 6 months of therapy (OR [95% CI]: 1.74 [1.01-3.00], p = 0.04). Rs1080985 might be useful as predictor of poor response to short-term donepezil treatment.

AB - Alzheimer's disease (AD) is a neurodegenerative disorder often treated with donepezil, an acetylcholinesterase inhibitor. Response to donepezil is variable, probably based on patients' genetic background in donepezil metabolizing enzymes, including cytochrome 2D6 (CYP2D6). We evaluated the association between clinical response to donepezil and a common variant (rs1080985) of CYP2D6, previously reported to be associated with poor response to the drug. In a sample of 415 AD cases, we found evidence of association between rs1080985 and response to donepezil after 6 months of therapy (OR [95% CI]: 1.74 [1.01-3.00], p = 0.04). Rs1080985 might be useful as predictor of poor response to short-term donepezil treatment.

KW - Alzheimer's disease

KW - apolipoprotein E

KW - CYP2D6

KW - donepezil

KW - pharmacogenetics

KW - rs1080985

UR - http://www.scopus.com/inward/record.url?scp=84862982197&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84862982197&partnerID=8YFLogxK

U2 - 10.3233/JAD-2012-112123

DO - 10.3233/JAD-2012-112123

M3 - Article

C2 - 22465999

AN - SCOPUS:84862982197

VL - 30

SP - 745

EP - 749

JO - Journal of Alzheimer's Disease

JF - Journal of Alzheimer's Disease

SN - 1387-2877

IS - 4

ER -